Tissue Engineering

Enzo receives approval to begin HIV clinical trial

Published in Gene Therapy Weekly, April 6th, 2006

Enzo Biochem, Inc. (ENZ) announced that Enzo Therapeutics, its wholly owned subsidiary, has received approval from the Committee on Human Research (CHR) at the University of California San Francisco (UCSF) to continue the clinical evaluation of the company's Stealth Vector HGTV43 gene construct for HIV-1 infection in a protocol that has been modified to increase the number of stem cells that engraft in the patient's bone marrow.

During the regulatory approval process that included a comprehensive review of the clinical protocol and safety features of the vector by the CHR, U.S Food and Drug Administration (FDA) and the Recombinant DNA Advisory Committee (RAC) of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2006-04-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry